ライフサイエンスコーパス: Crohn disease

1 (IBDs, which include ulcerative colitis and Crohn disease).

2 nt for the management of complex small bowel Crohn disease.

3 purely CRDD in the context of long-standing Crohn disease.

4 the pathogenetic parallels between CRDD and Crohn disease.

5 , lipid levels, height, body mass index, and Crohn disease.

6 when examining skin lesions in patients with Crohn disease.

7 se of LYG related to azathioprine therapy in Crohn disease.

8 are now the preferred treatment options for Crohn disease.

9 nsists of 2 subtypes: ulcerative colitis and Crohn disease.

10 erum in patients with ulcerative colitis and Crohn disease.

11 ncluding vitiligo, rheumatoid arthritis, and Crohn disease.

12 herapeutic interventions in the treatment of Crohn disease.

13 hisms (SNP) of the NOD2 gene associated with Crohn disease.

14 ociated with the increased susceptibility to Crohn disease.

15 E) alone, in the assessment of patients with Crohn disease.

16 ding of active inflammation in patients with Crohn disease.

17 prominently involved in the pathogenesis of Crohn disease.

18 s, particularly the apthoid lesions of early Crohn disease.

19 ulation leads to increased susceptibility to Crohn disease.

20 the demonstration of early apthous ulcers of Crohn disease.

21 are the most sensitive CT findings of active Crohn disease.

22 biopsy were examined for CT signs of active Crohn disease.

23 iologists examined CT images for findings of Crohn disease.

24 opic and histologic findings of inflammatory Crohn disease.

25 variants have been associated with risk for Crohn disease.

26 t in the overall management of patients with Crohn disease.

27 re highly associated with the development of Crohn disease.

28 and may prevent recurrence of postoperative Crohn disease.

29 other specific nutrient deficiencies seen in Crohn disease.

30 he pathogenesis, treatment, and morbidity of Crohn disease.

31 hibitor infliximab in surgical patients with Crohn disease.

32 increased T(H)1 responses characteristic of Crohn disease.

33 nal ileum, similar to what is found in human Crohn disease.

34 e, in 23 patients known or suspected to have Crohn disease.

35 ve small bowel inflammation in patients with Crohn disease.

36 rheumatoid arthritis, ulcerative colitis and Crohn disease.

37 currently the standard for imaging perianal Crohn disease.

38 nd imaging features of active terminal ileal Crohn disease.

39 e inflammatory terminal or neoterminal ileal Crohn disease.

40 liximab therapy in children with small bowel Crohn disease.

41 ts for quality and diagnostic confidence for Crohn disease.

42 onders among patients with clinically active Crohn disease.

43 RTE can be used to detect fibrosis in human Crohn disease.

44 ead use of HSCT for patients with refractory Crohn disease.

45 tically susceptible individuals, may lead to Crohn disease.

46 ients with no history of immunocompromise or Crohn disease.

47 et for several inflammatory diseases such as Crohn disease.

48 tation (HSCT) may benefit some patients with Crohn disease.

49 olymorphism analysis in 160 individuals with Crohn disease, 149 individuals with ulcerative colitis,

50 Thirty patients (15 Crohns disease, 15 ulcerative colitis) participated, and

51 0 [50%] women; 602 [56%] diagnosed as having Crohn disease), 919 (311 affected and 608 unaffected) we

52 ity of life (HRQOL) in pediatric small bowel Crohn disease (a) change in response to infliximab thera

53 ary end point comprising clinical remission (Crohn Disease Activity Index (CDAI) <150 [range, 0-600])

54 with severe Crohn disease (CD) defined as a Crohn Disease Activity Index (CDAI) greater than 250, an

55 l remission at week 8, measured by Pediatric Crohn Disease Activity Index (PCDAI) score and reduction

56 ory score <7, and/or a decrease >/=70 in the Crohn disease activity index score compared with baselin

57 onders among patients with clinically active Crohn disease after 6 weeks of pharmacologic treatment.

58 onfers increased risk for the development of Crohn disease, although the mechanisms by which single d

59 nety subjects (45 with active terminal ileal Crohn disease and 45 without Crohn disease) underwent CT

60 show applications to sequencing studies for Crohn disease and autism spectrum disorders.

61 n associated with two inflammatory diseases, Crohn disease and Blau syndrome, and are thought to cont

62 inherited inflammatory disorders, including Crohn disease and Blau syndrome.

63 ease based on ileocolonoscopy or established Crohn disease and imaging features of active terminal il

64 amiliar with MR imaging features of perianal Crohn disease and knowledgeable about what features may

65 effective therapy for active and fistulizing Crohn disease and may even be helpful in some patients w

66 gestive of neutrophil activity, and those in Crohn disease and mouse sera were suggestive of both mac

67 y fibrosis of the mucosal layer, develops in Crohn disease and not in ulcerative colitis.

68 Inflammatory bowel disease, especially Crohn disease and periodontal disease, appear to be over

69 diated intestinal inflammation, particularly Crohn disease and pouchitis, whereas viral, bacterial, f

70 tional disorders and ulcerative colitis from Crohn disease and predicting complications of disease.

71 er genetic risk locus shared by sarcoidosis, Crohn disease and psoriasis.

72 sent a categorization of complex small bowel Crohn disease and review its surgical treatment as a pot

73 in phase 2 clinical trials in patients with Crohn disease and rheumatoid arthritis.

74 es could contribute to complex diseases like Crohn disease and systemic lupus erythematosus, highligh

75 ependently implicated in diseases, including Crohn disease and systemic lupus erythematosus.

76 Application of this strategy to Crohn disease and type 2 diabetes predicts a number of g

77 ontributor to inflammatory diseases, such as Crohn disease and type 2 diabetes.

78 Crohn disease and ulcerative colitis are caused by an ex

79 Celiac disease, Crohn disease and ulcerative colitis are inflammatory di

80 ked to protection against the development of Crohn disease and ulcerative colitis in humans.

81 Crohn disease and ulcerative colitis patients exhibit pa

82 In both Crohn disease and ulcerative colitis there is an increas

83 Inflammatory bowel diseases (IBD), such as Crohn disease and ulcerative colitis, are chronic relaps

84 Inflammatory bowel disease (IBD), including Crohn disease and ulcerative colitis, is characterized b

85 pathogenesis of inflammatory bowel diseases-Crohn disease and ulcerative colitis-caused by untoward

86 has reached an incidence similar to that of Crohn disease and ulcerative colitis.

87 ic inflammatory bowel disease (IBD), such as Crohn disease and ulcerative colitis.

88 incipal forms of inflammatory bowel disease: Crohn disease and ulcerative colitis.

89 rize the latest information on biomarkers of Crohn disease and ulcerative colitis.

90 of some patients with previously intractable Crohn disease, and further TNF-alpha directed therapies

91 the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained a

92 disease, but not ulcerative colitis or ileal Crohn disease, and may prevent recurrence of postoperati

93 human diseases, including lupus, psoriasis, Crohn disease, and obesity.

94 s of obesity, gastrointestinal malignancies, Crohn disease, and perioperative complications including

95 doscopy had the highest diagnostic yield for Crohn disease, and SBFT had the lowest, but these differ

96 ut the risk allele for rheumatoid arthritis, Crohn disease, and ulcerative colitis.

97 ed to treat rheumatoid arthritis, psoriasis, Crohns disease, and osteoporosis, with a total market of

98 cutely inflamed from fibrotic intestine in a Crohn disease animal model.

99 anti-TNF therapy not only in RA but also in Crohn disease, ankylosing spondylitis, and several other

100 Women with Crohn disease appear to be at risk for early delivery an

101 n addition, advances in biologic therapy for Crohn disease are beginning to be formally evaluated in

102 dase deficiencies, short bowel syndrome, and Crohn disease are discussed.

103 e disease and one fourth of outpatients with Crohn disease are malnourished.

104 Emerging innovative treatments for perianal Crohn disease are now available and have the promise to

105 g oligomerization domain 2 (NOD2) protein to Crohn disease are still poorly understood.

106 ses (IBDs), including ulcerative colitis and Crohn disease, are chronic inflammatory disorders of the

107 -related p47 GTPase Irgm1 has been linked to Crohn disease as well as susceptibility to tuberculosis.

108 We also show that the three main Crohn disease-associated mutants of NOD2 (1007fs, R702W,

109 Crohn disease-associated mutations in CARD15/NOD2 predom

110 ettings as well as models recapitulating the Crohn disease-associated T300A polymorphism.

111 on and cancer, as well as conditions such as Crohn disease, atherosclerosis, and Alzheimer disease.

112 tive Crohn disease was active terminal ileal Crohn disease based on ileocolonoscopy or established Cr

113 hen flagellin, was elevated in patients with Crohn disease, but not in patients with ulcerative colit

114 and ciprofloxacin selectively treat colonic Crohn disease, but not ulcerative colitis or ileal Crohn

115 with disease chronicity and angiogenesis in Crohn disease, but not with histologic and clinical mark

116 ed to induce remission in moderate to severe Crohn disease, but they do not maintain remission.

117 The complexity of small bowel Crohn disease can be sorted into several categories: tec

118 This study included 148 mothers with Crohn disease (CD) and 194 with ulcerative colitis and 6

119 A total of 217 patients [123 with Crohn disease (CD) and 94 with ulcerative colitis (UC)]

120 nd uncovered significant association between Crohn Disease (CD) and the IL12/IL23 pathway, harboring

121 Crohn disease (CD) and ulcerative colitis (UC) are 2 com

122 Crohn disease (CD) and ulcerative colitis (UC) are overl

123 In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been

124 risk for IBD among those diagnosed as having Crohn disease (CD) and ulcerative colitis (UC).

125 tory but have been linked in some studies to Crohn disease (CD) and ulcerative colitis (UC).

126 that have been traditionally classified into Crohn disease (CD) and ulcerative colitis (UC).

127 y toward inflammatory bowel diseases (IBDs): Crohn disease (CD) and ulcerative colitis (UC).

128 Blau syndrome (BS) and Crohn disease (CD) are both characterized by granulomato

129 Early pathological descriptions of Crohn disease (CD) argued for a potential defect in lymp

130 o the Wellcome Trust Case-Control Consortium Crohn disease (CD) data set.

131 ansplantation (HSCT) in patients with severe Crohn disease (CD) defined as a Crohn Disease Activity I

132 Crohn disease (CD) exhibits a 2-4-fold increased frequen

133 The risk of Crohn disease (CD) has a large genetic component.

134 While Crohn disease (CD) has been clearly identified as a Th1

135 role of adherent-invasive E. coli (AIEC) in Crohn disease (CD) has been in debate for decades.

136 rs following ileocolonic resection (ICR) for Crohn disease (CD) in a nationwide cohort study SUMMARY

137 Crohn disease (CD) in children is associated with low bo

138 Crohn disease (CD) is a chronic inflammatory bowel disea

139 Crohn disease (CD) is a chronic inflammatory process of

140 Crohn disease (CD) is associated with osteoporosis and o

141 The use of narcotics among patients with Crohn disease (CD) is endemic.

142 severity of disease and additional surgery, Crohn disease (CD) may result in intestinal failure (IF)

143 It was approved for the treatment of Crohn disease (CD) on that basis, without specific studi

144 discrete-time hazard models for diagnosis of Crohn disease (CD) or ulcerative colitis (UC) among men

145 gut microbial community likely contribute to Crohn disease (CD) pathogenesis; however, direct evidenc

146 Family studies for Crohn disease (CD) report extensive linkage on chromosom

147 is useful in patients undergoing surgery for Crohn disease (CD) to avoid wide small-bowel resections.

148 he odds of having ulcerative colitis (UC) or Crohn disease (CD) were elevated in carriers of the SLC2

149 Data were obtained from 409 patients with Crohn disease (CD) who had undergone >=1 ileocolectomies

150 e colitis (UC) with concurrent colectomy and Crohn disease (CD) with concurrent small bowel resection

151 Studies of Crohn disease (CD), a chronic inflammatory disease of th

152 n genetic risk factor in the pathogenesis of Crohn disease (CD), a chronic relapsing inflammatory dis

153 Crohn disease (CD), an inflammatory bowel disease, is a

154 inflamed intestinal mucosa of patients with Crohn disease (CD), but not in patients with ulcerative

155 testinal fibrosis is a major complication of Crohn disease (CD), but the precise mechanism by which i

156 e associated with rheumatoid arthritis (RA), Crohn disease (CD), type 1 diabetes (T1D), or type 2 dia

157 ole in chronic inflammatory diseases such as Crohn disease (CD), ulcerative colitis, psoriasis, and t

158 IS) and its effects on bowel preservation in Crohn disease (CD).

159 ence of periodontal disease in patients with Crohn disease (CD).

160 Here, we concentrate on an application to Crohn disease (CD).

161 anal stenosis are manifestations of perianal Crohn disease (CD).

162 osus, and variants have been associated with Crohn disease (CD).

163 rrence score and surgical recurrence rate in Crohn disease (CD).

164 e clinically and histologically from that of Crohn disease (CD); however, mucocutaneous granulomatous

165 dentified but 22 subsequently proved to have Crohns disease (CD).

166 types related to inflammatory bowel disease (Crohn disease [CD] and ulcerative colitis [UC]) and diab

167 ergence of inflammatory bowel diseases (IBD: Crohn disease [CD] and ulcerative colitis [UC]) where in

168 is (RA) and inflammatory bowel disease (IBD; Crohn disease [CD], ulcerative colitis [UC]) and is inve

169 ation in enterocytes have been documented in Crohn disease, celiac disease, surgical stress, and inte

170 For more information on adalimumab in Crohn disease, click here.

171 7 levels were decreased in actively inflamed Crohn disease colonic tissues, where CD98 expression was

172 a sensitivity of 90% (18 of 20) for definite Crohn disease (compared with a sensitivity of 80% [16 of

173 cidences of pediatric ulcerative colitis and Crohn disease continue to evolve with geographic variati

174 e presentation of eating disorders including Crohn disease (CrD), celiac disease, gastroesophageal re

175 a diverse range of simulated data sets and a Crohn disease data set was assessed.

176 disease-associated genetic variations in the Crohn disease data set.

177 The methods are applied to a Crohn disease data set.

178 P = 5.73 x 10-6 for AD, and 6.57 x 10-5 for Crohn disease) demonstrated the same direction of alleli

179 ed clinical trial of 56 children with active Crohn disease despite immunosuppressive treatment, condu

180 raphy for active inflammatory terminal ileal Crohn disease, despite an inferior subjective image qual

181 infectious (HIV) and noninfectious (CGD and Crohn disease) diseases that have been associated with i

182 Eleven consecutive patients with Crohn disease (eight female patients, three men; mean ag

183 in responders (those with a decrease in the Crohn disease endoscopic index of severity score of 25-4

184 was the most sensitive visual CT finding of Crohn disease for both radiologists.

185 Fibrosis is a serious complication of Crohn disease for which there is no effective therapy.

186 nd affected gut segments in 10 patients with Crohn disease (four women, six men; median age, 49 years

187 In patients with Crohn disease, gadolinium-enhanced fat-suppressed spoile

188 Ulcerative colitis and Crohn disease (granulomatous colitis) are rarely associa

189 e principles of modern surgical treatment of Crohn disease have evolved to bowel conservation such as

190 rich repeat domain, which is associated with Crohn disease, impairs the interaction with FRMPD2, and

191 Seventy-nine patients presented RVF due to Crohn disease in 34 (43%), postoperative in 25 (32%), ob

192 ials have evaluated new drugs for refractory Crohn disease in children.

193 s, 80%) for enabling the detection of active Crohn disease in comparison with CT enteroclysis with na

194 proposed to be at least one of the causes of Crohn disease in humans.

195 rminal ileoscopy for the detection of active Crohn disease in the terminal ileum.

196 is distinguished from granulomatous colitis (Crohn disease) in terms of location of involvement, exte

197 ly our approach to a genome-wide analysis of Crohn disease, in which we replicate association with 17

198 sceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic p

199 diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic p

200 axis to be potentially exploitable in future Crohn disease interventions.

201 d CTE images were each visually assessed for Crohn disease involvement in 54 bowel segments with path

202 The relative risk of developing Crohn disease is estimated to be in the range of 2 to 3

203 Crohn disease is frequently complicated by various skin

204 lysis study where the pretest probability of Crohn disease is high.

205 The most common surgery performed for Crohn disease is ileocolectomy.

206 Crohn disease is immunologically mediated and characteri

207 Malnutrition, which can be present even when Crohn disease is in remission, can affect growth, cellul

208 Pediatric-onset Crohn disease is more aggressive than adult-onset diseas

209 nding oligomerization domain 2 (NOD2), cause Crohn disease is poorly understood.

210 Appropriate surgical management of Crohn disease is predicated on multiple variables, but s

211 Treatment of Crohn disease is rapidly evolving, with the induction of

212 conditions such as rheumatoid arthritis and Crohn disease, is in part driven by discordant productio

213 ory bowel disease , particularly small bowel Crohn disease, it has also proven useful in assessing th

214 reover, NOD2 deficiency or the presence of a Crohn disease-like Card15 mutation increased Toll-like r

215 y improves disease in a spontaneous model of Crohn Disease-like ileitis.

216 on is also implicated in the pathogenesis of Crohn disease, linking these otherwise unrelated entitie

217 enesis of chronic inflammatory diseases like Crohn disease, might thus be considered as a major actor

218 An acute inflammation Crohn disease model was produced by treating eight Lewis

219 disease, multifocal choroiditis, panuveitis, Crohn disease, multiple sclerosis, and relapsing polycho

220 associated with autoimmune diseases such as Crohn disease, multiple sclerosis, and ulcerative coliti

221 ariants predisposing to atrial fibrillation, Crohn disease, multiple sclerosis, rheumatoid arthritis,

222 (n = 16), tubo-ovarian inflammation (n = 5), Crohn disease (n = 10), and internal bowel fistula due t

223 may contribute to the clinical phenotype of Crohn disease, necrotizing enterocolitis, and, perhaps,

224 ith impaired quality of life from refractory Crohn disease not amenable to surgery despite treatment

225 Among adult patients with refractory Crohn disease not amenable to surgery who had impaired q

226 Understanding the complexity of Crohn disease of the small bowel is important for the su

227 The clinical presentations of Crohn disease of the small bowel vary from low to high c

228 re in patients with extensive fibrostenosing Crohn disease of the small bowel.

229 dge of the effects of ulcerative colitis and Crohn disease on fetal outcome.

230 ty-six year old Caucasian woman with colonic Crohn disease on maintenance azathioprine therapy presen

231 categorized as either ulcerative colitis or Crohn disease on the basis of clinical, radiologic, and

232 d, the level of HIV control, and the risk of Crohn disease only among those carrying an intact miR-14

233 had a secondary ICD-9-CM diagnosis code for Crohn disease or if the patient was not continuously enr

234 e of each of these cell types in fibrosis in Crohn disease or other inflammatory bowel diseases is de

235 e), juvenile RA, inflammatory bowel disease (Crohn disease or ulcerative colitis), psoriasis, and pri

236 ents with inflammatory bowel disease, either Crohn disease or ulcerative colitis, are at an increased

237 h colonic levels of CCDC88b in patients with Crohn disease or ulcerative colitis, identifying that ex

238 eroids and other immunosuppressive agents in Crohn disease or ulcerative colitis.

239 dy-mass index (BMI), and height, but not for Crohn disease or ulcerative colitis.

240 ease (OR 0.85 [95% CI 0.74-0.98]; p < 0.03), Crohn disease (OR 0.81 [95% CI 0.70-0.94]; p < 0.005), p

241 ickness correlated significantly with active Crohn disease (P < .001).

242 ssociated stimulated dendritic cell genes in Crohn disease (p = 1.6 x 10(-5)).

243 ion false discovery rate P = .009 for AD and Crohn disease, P = 5.73 x 10-6 for AD, and 6.57 x 10-5 f

244 ergent genes and pathways in 177 small bowel Crohn disease patients and controls.

245 evaluation of both experimental colitis and Crohn disease patients and thereby offers promising tran

246 terocytes from the inflamed ileal tissues of Crohn disease patients compared to uninflamed tissues, r

247 In addition, (18)F-FDG PET/CT scans of 25 Crohn disease patients were analyzed, and colonic (18)F-

248 hy may effectively be used to follow up both Crohn disease patients without jejunal disease and in pe

249 an Th17 cells, including those isolated from Crohn disease patients, and it is linked to disease, as

250 n ILCs expressing NKp44 in tonsils and PB of Crohn disease patients, and relatively fewer CD62L(+) IL

251 ession in a subset of ulcerative colitis and Crohn disease patients.

252 e reminiscent of fibrotic strictures seen in Crohn disease patients.

253 ly fewer CD62L(+) ILCP were present in PB of Crohn disease patients.

254 prebiotics can potentially prevent and treat Crohn disease, pouchitis, and possibly ulcerative coliti

255 An 81-year-old woman with Crohn disease presented with fever and an acute eruption

256 as previously reported to be associated with Crohn disease, psoriasis, alopecia areata, and leprosy.

257 ix children with newly diagnosed small bowel Crohn disease receiving infliximab therapy were prospect

258 Use of probiotics in Crohn disease remains unsubstantiated.

259 f the CARD15/NOD2 protein as contributing to Crohn disease represents a major advance in defining dis

260 rition as an alternative to major surgery in Crohn disease should be considered.

261 housands of control subjects from studies of Crohn disease, showing how it controls false positives,

262 patients, overlapping substantially with the Crohn disease signature.

263 ells that overlapped to some extent with the Crohn disease signature.

264 In Crohn disease similar remission rates are achieved with

265 Numerous case reports of angioectasias, Crohn disease, small bowel tumors, and other small bowel

266 with a specific role in the investigation of Crohn disease, small-bowel obstruction, and unexplained

267 Pancreatic autoantibodies are Crohn disease-specific serologic markers.

268 In children and adolescents with refractory Crohn disease, thalidomide compared with placebo resulte

269 vern, PA) for the treatment of children with Crohn disease that does not respond to conventional mana

270 gh mesalamines are still often used to treat Crohn disease, the evidence for their efficacy is lackin

271 effective in the treatment of patients with Crohn disease, their use should continue to be restricte

272 the inflamed intestine has revealed that in Crohn disease there is predominantly a T helper cell typ

273 ects, whereas in patients with HIV, CGD, and Crohn disease, there was a significant increase in the p

274 The progression of Crohn disease to intestinal stricture formation is poorl

275 ents underwent HSCT and 22 received standard Crohn disease treatment (controls).

276 All were given standard Crohn disease treatment as needed.

277 ion, diet, and antibiotics and shed light on Crohn disease treatments.

278 ies of the distal gut microbiome, such as in Crohn disease, ulcerative colitis, and infectious coliti

279 d pleiotropy between PD and type 1 diabetes, Crohn disease, ulcerative colitis, rheumatoid arthritis,

280 Genomics of Alzheimer's Project stage 1) and Crohn disease, ulcerative colitis, rheumatoid arthritis,

281 itis, Graves disease, Hashimoto thyroiditis, Crohn disease, ulcerative colitis, systemic lupus erythe

282 The second patient with Crohn disease underwent emergent laparotomy for a perfor

283 terminal ileal Crohn disease and 45 without Crohn disease) underwent CT enterography with a dual-sou

284 eference standard for confirmation of active Crohn disease was active terminal ileal Crohn disease ba

285 Crohn disease was depicted by capsule endoscopy in 12 pa

286 phagy in human inflammatory diseases such as Crohn disease was first identified by genome-wide associ

287 Thirteen patients with Crohn disease were prospectively enrolled in this pilot

288 o have or suspected of having nonobstructive Crohn disease were recruited.

289 Findings consistent with Crohn disease were tabulated for each imaging examinatio

290 nd CT enterography may depict nonobstructive Crohn disease when techniques such as ileoscopy and SBFT

291 associated with a higher susceptibility for Crohn disease, which highlights the physiological import

292 Mutations in NOD2 are highly associated with Crohn disease, which is characterized by dysregulated in

293 is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagoni

294 equently than placebo in adult patients with Crohn disease who cannot tolerate infliximab or have sym

295 een evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agen

296 hy images were evaluated in 19 patients with Crohn disease who had strictures that underwent surgical

297 oncurrent use of infliximab in patients with Crohn disease who have undergone surgery.

298 ars +/- 9) with a proved diagnosis of active Crohn disease who were scheduled to begin therapy with b

299 Flagellin is an immunodominant Ag in Crohn disease, with many patients showing anti-flagellin

300 reviews each category of complex small bowel Crohn disease, with special emphasis on appropriate surg